Answers are grounded in this paper and cite their sources.
Background Electrical cardioversion (DCCV) is commonly used for rhythm-control in patients with persistent AF. Use of anti-arrhythmic drugs (AADs) increases rates of acute conversion and longer-term maintenance of sinus rhythm (SR) following DCCV. Of these, Amiodarone is the most effective but has a high side-effect burden. Ranolazine, currently licensed for angina, has been shown to have AF-suppressive effects and works synergistically with Class III AADs. Purpose We aimed to assess outcomes following DCCV in patients treated with a Class III AAD, Ranolazine or in combination at a single UK tertiary Cardiology centre. Methods We retrospectively reviewed DCCV lists from June 2020-February 2022. Patients undergoing DCCV on a Class III AAD (Amiodarone/Dronedarone), Ranolazine or a combination of the two and with documented 1-year follow-up were included. Patients who underwent AF ablation during the follow-up period having remained in SR up to that point were excluded. Acute DCCV success and maintenance of SR at 1-year follow-up were recorded. Results A total of 350 patients underwent DCCV during the study period, of whom 102 (29.1%) were on an AAD. After exclusions, 78 patients were included, as follows: Amiodarone - n=30; Dronedarone - n=23; Ranolazine - n=11; combined Ranolazine + Class III AAD - n=14. Acute outcomes: The proportion of patients achieving SR acutely post-DCCV was as follows: Amiodarone: 27/30 (90.0%) Dronedarone: 21/23 (91.3%) Any Class III AAD: 48/53 (90.6%) Ranolazine: 10/11 (90.9 %) Combined Ranolazine + Class III AAD: 14/14 (100%). 1-year follow-up outcomes (Figure 1): The proportion of patients who had remained in SR at 1 year (mean follow-up 11±1.9 months – similar for all 4 groups) was as follows: Amiodarone: 12/30 (40.0%) Dronedarone: 4/23 (17.4%) Any Class III AAD: 16/53 (30.2%) Ranolazine: 3/11 (27.2%) Combined Ranolazine and Class III AAD: 8/14 (53.3%). Despite including 5 patients (35.3%) who had previously failed an AAD monotherapy, the group taking a combination of Ranolazine and a Class III AAD were numerically more likely to remain in SR at 1-year follow-up than those on Amiodarone or Ranolazine, though neither reached significance. However, combination therapy was significantly more effective than Dronedarone monotherapy (P=0.03) and there was a trend towards improved efficacy compared to any Class III AAD (53.3% vs. 30.2%, P=0.11). There were no significant differences between the 3 monotherapy treatments. Conclusion A combination of Ranolazine and Class III AAD may improve maintenance of SR 1 year post-DCCV compared to a Class III AAD alone. Ranolazine also shows comparable efficacy to traditional Class III agents and could therefore be considered as an alternative for patients in whom a Class III AAD is not desirable. Larger randomised multi-centre trials are warranted to evaluate the efficacy and safety of these treatment strategies.
No takes yet. Share an insight, caveat, or question.
Raman et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: